Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806694 | 0.98 | KISS1R (0.36) | KISS1RHTR1BLMNAHRH1HTR2A | |
| SCHEMBL21106870 | 0.91 | EPHX1 (0.39) | KISS1RHTR1BLMNAHRH1HTR2A | |
| SCHEMBL23568411 | 0.91 | LMNA (0.36) | KISS1RHTR1BLMNAHRH1HTR2A | |
| SCHEMBL9947080 | 0.91 | KISS1R (0.37) | KISS1RHTR1BHRH1HTR2AEPHX1 | |
| SCHEMBL9947078 | 0.91 | KISS1R (0.33) | KISS1RLMNA | |
| SCHEMBL24512851 | 0.89 | MEN1 (0.35) | KISS1RLMNA | |
| SCHEMBL20850674 | 0.89 | MEN1 (0.35) | KISS1RLMNA | |
| SCHEMBL25123362 | 0.89 | MEN1 (0.35) | KISS1RLMNA | |
| SCHEMBL8352992 | 0.83 | HTR1B (0.46) | HTR1BHRH1EPHX1KDM4EALDH1A1 | |
| SCHEMBL1192955 | 0.83 | LMNA (0.45) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KISS1R 2435/4885HTR1B 3501/4885LMNA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.